US4433059A
(en)
|
1981-09-08 |
1984-02-21 |
Ortho Diagnostic Systems Inc. |
Double antibody conjugate
|
US4444878A
(en)
|
1981-12-21 |
1984-04-24 |
Boston Biomedical Research Institute, Inc. |
Bispecific antibody determinants
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
JPS6147500A
(ja)
|
1984-08-15 |
1986-03-07 |
Res Dev Corp Of Japan |
キメラモノクロ−ナル抗体及びその製造法
|
EP0173494A3
(en)
|
1984-08-27 |
1987-11-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric receptors by dna splicing and expression
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
JPS61134325A
(ja)
|
1984-12-04 |
1986-06-21 |
Teijin Ltd |
ハイブリツド抗体遺伝子の発現方法
|
US4978672A
(en)
|
1986-03-07 |
1990-12-18 |
Ciba-Geigy Corporation |
Alpha-heterocyclc substituted tolunitriles
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
US5869620A
(en)
|
1986-09-02 |
1999-02-09 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2 Inc |
Geänderte antikörper.
|
EP0296122B1
(en)
|
1987-06-17 |
1993-09-29 |
Sandoz Ag |
Cyclosporins and their use as pharmaceuticals
|
JPH021556A
(ja)
|
1988-06-09 |
1990-01-05 |
Snow Brand Milk Prod Co Ltd |
ハイブリッド抗体及びその作製方法
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
DE768377T1
(de)
|
1988-09-02 |
1998-01-02 |
Dyax Corp |
Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
GB8905669D0
(en)
|
1989-03-13 |
1989-04-26 |
Celltech Ltd |
Modified antibodies
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
WO1991000906A1
(en)
|
1989-07-12 |
1991-01-24 |
Genetics Institute, Inc. |
Chimeric and transgenic animals capable of producing human antibodies
|
WO1991003493A1
(en)
|
1989-08-29 |
1991-03-21 |
The University Of Southampton |
Bi-or trispecific (fab)3 or (fab)4 conjugates
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
EP1690935A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
US5273743A
(en)
|
1990-03-09 |
1993-12-28 |
Hybritech Incorporated |
Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
GB9012995D0
(en)
|
1990-06-11 |
1990-08-01 |
Celltech Ltd |
Multivalent antigen-binding proteins
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
CA2109602C
(en)
|
1990-07-10 |
2002-10-01 |
Gregory P. Winter |
Methods for producing members of specific binding pairs
|
US5612205A
(en)
|
1990-08-29 |
1997-03-18 |
Genpharm International, Incorporated |
Homologous recombination in mammalian cells
|
KR100272077B1
(ko)
|
1990-08-29 |
2000-11-15 |
젠팜인터내셔날,인코포레이티드 |
이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
|
ATE164395T1
(de)
|
1990-12-03 |
1998-04-15 |
Genentech Inc |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
US5582996A
(en)
|
1990-12-04 |
1996-12-10 |
The Wistar Institute Of Anatomy & Biology |
Bifunctional antibodies and method of preparing same
|
JP4146512B2
(ja)
|
1991-03-01 |
2008-09-10 |
ダイアックス コープ. |
小型タンパク質
|
US20030206899A1
(en)
|
1991-03-29 |
2003-11-06 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists
|
US6582959B2
(en)
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
ES2315612T3
(es)
|
1991-04-10 |
2009-04-01 |
The Scripps Research Institute |
Genotecas de receptores heterodimericos usando fagemidos.
|
EP0519596B1
(en)
|
1991-05-17 |
2005-02-23 |
Merck & Co. Inc. |
A method for reducing the immunogenicity of antibody variable domains
|
DE4118120A1
(de)
|
1991-06-03 |
1992-12-10 |
Behringwerke Ag |
Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
|
US6511663B1
(en)
|
1991-06-11 |
2003-01-28 |
Celltech R&D Limited |
Tri- and tetra-valent monospecific antigen-binding proteins
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
DE4122599C2
(de)
|
1991-07-08 |
1993-11-11 |
Deutsches Krebsforsch |
Phagemid zum Screenen von Antikörpern
|
US5932448A
(en)
|
1991-11-29 |
1999-08-03 |
Protein Design Labs., Inc. |
Bispecific antibody heterodimers
|
DE69309472T2
(de)
|
1992-01-23 |
1997-10-23 |
Merck Patent Gmbh |
Fusionsproteine von monomeren und dimeren von antikörperfragmenten
|
EP1997894B1
(en)
|
1992-02-06 |
2011-03-30 |
Novartis Vaccines and Diagnostics, Inc. |
Biosynthetic binding protein for cancer marker
|
DE69231123T2
(de)
|
1992-03-25 |
2001-02-15 |
Immunogen Inc |
Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065
|
WO1993023537A1
(en)
|
1992-05-08 |
1993-11-25 |
Creative Biomolecules |
Chimeric multivalent protein analogues and methods of use thereof
|
DE69330523D1
(de)
|
1992-08-21 |
2001-09-06 |
Vrije Universiteit Brussel Bru |
Immunoglobuline ohne leichte ketten
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
JPH08504320A
(ja)
|
1992-09-25 |
1996-05-14 |
コモンウエルス・サイエンティフィック・アンド・インダストリアル・リサーチ・オーガニゼーション |
標的結合性ポリペプチド
|
GB9221657D0
(en)
|
1992-10-15 |
1992-11-25 |
Scotgen Ltd |
Recombinant bispecific antibodies
|
ES2173873T5
(es)
|
1992-10-28 |
2007-03-01 |
Genentech, Inc. |
Utilizacion de anticuerpos anti-vegf para el tratamiento del cancer.
|
DE69232604T2
(de)
|
1992-11-04 |
2002-11-07 |
City Of Hope Duarte |
Antikörperkonstrukte
|
GB9323648D0
(en)
|
1992-11-23 |
1994-01-05 |
Zeneca Ltd |
Proteins
|
DK0672142T3
(da)
|
1992-12-04 |
2001-06-18 |
Medical Res Council |
Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
|
US6476198B1
(en)
|
1993-07-13 |
2002-11-05 |
The Scripps Research Institute |
Multispecific and multivalent antigen-binding polypeptide molecules
|
US5635602A
(en)
|
1993-08-13 |
1997-06-03 |
The Regents Of The University Of California |
Design and synthesis of bispecific DNA-antibody conjugates
|
WO1995009917A1
(en)
|
1993-10-07 |
1995-04-13 |
The Regents Of The University Of California |
Genetically engineered bispecific tetravalent antibodies
|
JP3659261B2
(ja)
|
1994-10-20 |
2005-06-15 |
モルフォシス・アクチェンゲゼルシャフト |
組換体タンパク質の多機能性複合体への標的化ヘテロ結合
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
IL117645A
(en)
|
1995-03-30 |
2005-08-31 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
|
DE69633175T2
(de)
|
1995-05-23 |
2005-08-11 |
Morphosys Ag |
Multimere proteine
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
WO1997014719A1
(en)
|
1995-10-16 |
1997-04-24 |
Unilever N.V. |
A bifunctional or bivalent antibody fragment analogue
|
EP0894135B1
(en)
|
1996-04-04 |
2004-08-11 |
Unilever Plc |
Multivalent and multispecific antigen-binding protein
|
TW533205B
(en)
|
1996-06-25 |
2003-05-21 |
Novartis Ag |
Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
DK0920505T3
(da)
|
1996-08-16 |
2008-09-08 |
Schering Corp |
Pattedyrcelleoverfladeantigener og tilhörende reagenser
|
ES2273415T3
(es)
|
1997-04-07 |
2007-05-01 |
Genentech, Inc. |
Anticuerpos anti-vegf.
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
CN104231078A
(zh)
|
1997-04-07 |
2014-12-24 |
基因技术股份有限公司 |
抗-血管内皮生长因子的抗体
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
WO1998048837A1
(en)
|
1997-04-30 |
1998-11-05 |
Enzon, Inc. |
Polyalkylene oxide-modified single chain polypeptides
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
US20030207346A1
(en)
|
1997-05-02 |
2003-11-06 |
William R. Arathoon |
Method for making multispecific antibodies having heteromultimeric and common components
|
WO1998056906A1
(en)
|
1997-06-11 |
1998-12-17 |
Thoegersen Hans Christian |
Trimerising module
|
CO4940418A1
(es)
|
1997-07-18 |
2000-07-24 |
Novartis Ag |
Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
|
US6689607B2
(en)
|
1997-10-21 |
2004-02-10 |
Human Genome Sciences, Inc. |
Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
|
US6509173B1
(en)
|
1997-10-21 |
2003-01-21 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
|
EP1027439B1
(en)
|
1997-10-27 |
2010-03-17 |
Bac Ip B.V. |
Multivalent antigen-binding proteins
|
AU2719099A
(en)
|
1998-01-23 |
1999-08-09 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Multipurpose antibody derivatives
|
JP2002502607A
(ja)
|
1998-02-09 |
2002-01-29 |
ジェネンテク・インコーポレイテッド |
新規な腫瘍壊死因子レセプター相同体及びそれをコードする核酸
|
HUP9900956A2
(hu)
|
1998-04-09 |
2002-04-29 |
Aventis Pharma Deutschland Gmbh. |
Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk
|
WO1999052552A1
(en)
|
1998-04-15 |
1999-10-21 |
Brigham & Women's Hospital, Inc. |
T cell inhibitory receptor compositions and uses thereof
|
DE19819846B4
(de)
|
1998-05-05 |
2016-11-24 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Multivalente Antikörper-Konstrukte
|
GB9812545D0
(en)
|
1998-06-10 |
1998-08-05 |
Celltech Therapeutics Ltd |
Biological products
|
ATE251181T1
(de)
|
1998-07-28 |
2003-10-15 |
Micromet Ag |
Heterominikörper
|
US6333396B1
(en)
|
1998-10-20 |
2001-12-25 |
Enzon, Inc. |
Method for targeted delivery of nucleic acids
|
US6703020B1
(en)
|
1999-04-28 |
2004-03-09 |
Board Of Regents, The University Of Texas System |
Antibody conjugate methods for selectively inhibiting VEGF
|
US7527787B2
(en)
|
2005-10-19 |
2009-05-05 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
ES2295040T3
(es)
|
1999-07-12 |
2008-04-16 |
Genentech, Inc. |
Promocion o inhibicion de la angiogenesis y cardiovascularizacion mediante homologos del ligando / receptor del factor de necrosis del tumor.
|
GB0018891D0
(en)
|
2000-08-01 |
2000-09-20 |
Novartis Ag |
Organic compounds
|
JP2003531588A
(ja)
|
2000-04-11 |
2003-10-28 |
ジェネンテック・インコーポレーテッド |
多価抗体とその用途
|
WO2001090192A2
(en)
|
2000-05-24 |
2001-11-29 |
Imclone Systems Incorporated |
Bispecific immunoglobulin-like antigen binding proteins and method of production
|
CA2410551A1
(en)
|
2000-06-30 |
2002-01-10 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) |
Heterodimeric fusion proteins
|
CN1461344A
(zh)
|
2000-07-25 |
2003-12-10 |
免疫医疗公司 |
多价靶结合蛋白
|
GB0020685D0
(en)
|
2000-08-22 |
2000-10-11 |
Novartis Ag |
Organic compounds
|
KR100870123B1
(ko)
|
2000-10-20 |
2008-11-25 |
츄가이 세이야꾸 가부시키가이샤 |
저분자화 아고니스트 항체
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
WO2002072635A2
(en)
|
2001-03-13 |
2002-09-19 |
University College London |
Specific binding members
|
DK1399484T3
(da)
|
2001-06-28 |
2010-11-08 |
Domantis Ltd |
Dobbelt-specifik ligand og anvendelse af denne
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
EP1293514B1
(en)
|
2001-09-14 |
2006-11-29 |
Affimed Therapeutics AG |
Multimeric single chain tandem Fv-antibodies
|
PL211461B1
(pl)
|
2001-10-30 |
2012-05-31 |
Dana Farber Cancer Inst Inc |
Zastosowanie pochodnych staurosporyny do wytwarzania kompozycji farmaceutycznej do leczenia lub zapobiegania białaczkom i zespołom mielodysplastycznym, preparat farmaceutyczny do leczenia białaczek i zestaw farmaceutyczny
|
AU2002357072A1
(en)
|
2001-12-07 |
2003-06-23 |
Centocor, Inc. |
Pseudo-antibody constructs
|
MXPA04007402A
(es)
|
2002-02-01 |
2005-06-17 |
Ariad Gene Therapeutics Inc |
Compuestos que contienen fosforo y usos de los mismos.
|
JP2006502091A
(ja)
|
2002-03-01 |
2006-01-19 |
イミューノメディクス、インコーポレイテッド |
クリアランス速度を高めるための二重特異性抗体点変異
|
PT3000810T
(pt)
|
2002-03-13 |
2017-10-25 |
Array Biopharma Inc |
Derivados de benzimidazole alquilado n3 como inibidores de mek
|
AU2003227504A1
(en)
|
2002-04-15 |
2003-10-27 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD OF CONSTRUCTING scDb LIBRARY
|
US7495090B2
(en)
|
2002-05-23 |
2009-02-24 |
The Regents Of The University Of California |
Nucleic acids encoding chimeric CD154 polypeptides
|
GB0215676D0
(en)
|
2002-07-05 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
US20040047858A1
(en)
|
2002-09-11 |
2004-03-11 |
Blumberg Richard S. |
Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
|
EP2287192B1
(en)
|
2002-11-15 |
2015-08-26 |
Novartis Vaccines and Diagnostics, Inc. |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
US7488802B2
(en)
|
2002-12-23 |
2009-02-10 |
Wyeth |
Antibodies against PD-1
|
GB0230203D0
(en)
|
2002-12-27 |
2003-02-05 |
Domantis Ltd |
Fc fusion
|
US7387271B2
(en)
|
2002-12-30 |
2008-06-17 |
3M Innovative Properties Company |
Immunostimulatory combinations
|
EP1611112B1
(en)
|
2003-02-11 |
2012-08-22 |
Vernalis (Cambridge) Limited |
Isoxazole compounds as inhibitors of heat shock proteins
|
GB0305702D0
(en)
|
2003-03-12 |
2003-04-16 |
Univ Birmingham |
Bispecific antibodies
|
AU2004232928A1
(en)
|
2003-04-22 |
2004-11-04 |
Ibc Pharmaceuticals |
Polyvalent protein complex
|
BRPI0410785A
(pt)
|
2003-05-23 |
2006-06-20 |
Wyeth Corp |
molécula de ácido nucleico isolada, célula hospedeira, animal transgênico não humano, proteìna isolada, oligonucleotìdeo anti-sentido, molécula de sirna, anticorpo isolado, métodos de triagem quanto aos compostos de teste capazes de inibir, de intensificar ou imitar a interação do gitrl com o gitr, para diagnosticar doenças, para tratar um paciente em risco ou diagnosticado com uma doença, para induzir e para inibir a proliferação de uma população celular contendo células t efetoras, de bloquear a supressão e de supressão de uma população celular que inclua células t efetoras na presença de células t reguladoras cd4+cd25+, e para tratar uma doença, composição farmacêutica, e, adjuvante de vacina
|
KR20120104408A
(ko)
|
2003-05-30 |
2012-09-20 |
제넨테크, 인크. |
항-vegf 항체를 사용한 치료
|
NZ544924A
(en)
|
2003-06-27 |
2009-03-31 |
Biogen Idec Inc |
Modified binding molecules comprising connecting peptides
|
WO2005004809A2
(en)
|
2003-07-01 |
2005-01-20 |
Immunomedics, Inc. |
Multivalent carriers of bi-specific antibodies
|
WO2005007190A1
(en)
|
2003-07-11 |
2005-01-27 |
Schering Corporation |
Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
|
US7696322B2
(en)
|
2003-07-28 |
2010-04-13 |
Catalent Pharma Solutions, Inc. |
Fusion antibodies
|
WO2005044853A2
(en)
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
CA2542046A1
(en)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
Fused protein composition
|
JP2007509185A
(ja)
|
2003-10-27 |
2007-04-12 |
ノバルティス アクチエンゲゼルシャフト |
βアミロイド産生および/または凝集と関係がある神経障害および血管障害の処置のためのインドリル−ピロールジオン誘導体
|
EP1692318A4
(en)
|
2003-12-02 |
2008-04-02 |
Genzyme Corp |
COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LUNG CANCER
|
WO2005062916A2
(en)
|
2003-12-22 |
2005-07-14 |
Centocor, Inc. |
Methods for generating multimeric molecules
|
GB0329825D0
(en)
|
2003-12-23 |
2004-01-28 |
Celltech R&D Ltd |
Biological products
|
US20050266425A1
(en)
|
2003-12-31 |
2005-12-01 |
Vaccinex, Inc. |
Methods for producing and identifying multispecific antibodies
|
CA2552750C
(en)
|
2004-01-07 |
2021-11-09 |
Chiron Corporation |
M-csf-specific monoclonal antibody and uses thereof
|
AU2005207946A1
(en)
|
2004-01-23 |
2005-08-11 |
Amgen Inc. |
Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
|
US8383575B2
(en)
|
2004-01-30 |
2013-02-26 |
Paul Scherrer Institut |
(DI)barnase-barstar complexes
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
WO2005113556A1
(en)
|
2004-05-13 |
2005-12-01 |
Icos Corporation |
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
|
WO2006083289A2
(en)
|
2004-06-04 |
2006-08-10 |
Duke University |
Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
|
PL1761528T3
(pl)
|
2004-06-11 |
2008-05-30 |
Japan Tobacco Inc |
Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-D]pirymidyny i związki pokrewne do leczenia raka
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
US20060009360A1
(en)
|
2004-06-25 |
2006-01-12 |
Robert Pifer |
New adjuvant composition
|
EP1786918A4
(en)
|
2004-07-17 |
2009-02-11 |
Imclone Systems Inc |
NEW BISPECIFIC ANTIBODY TETRAVALENT
|
GB0417487D0
(en)
|
2004-08-05 |
2004-09-08 |
Novartis Ag |
Organic compound
|
EP1789446A2
(en)
|
2004-09-02 |
2007-05-30 |
Genentech, Inc. |
Heteromultimeric molecules
|
CN104177497B
(zh)
|
2005-02-08 |
2018-01-16 |
根茨美公司 |
针对TGFβ的抗体
|
DK2343320T3
(da)
|
2005-03-25 |
2018-01-29 |
Gitr Inc |
Anti-gitr-antistoffer og anvendelser deraf
|
EP3623473A1
(en)
|
2005-03-31 |
2020-03-18 |
Chugai Seiyaku Kabushiki Kaisha |
Process for production of polypeptide by regulation of assembly
|
CN101484182B
(zh)
|
2005-04-06 |
2014-06-11 |
Ibc药品公司 |
由同二聚体、同四聚体或二聚体的二聚体组成的稳定连接复合体的生产方法及用途
|
JP5838021B2
(ja)
|
2005-04-15 |
2015-12-24 |
マクロジェニクス,インコーポレーテッド |
共有結合型ダイアボディとその使用
|
DK1877090T3
(da)
|
2005-05-06 |
2014-04-14 |
Providence Health System |
Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf
|
DK2161336T4
(en)
|
2005-05-09 |
2017-04-24 |
Ono Pharmaceutical Co |
Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
US20060263367A1
(en)
|
2005-05-23 |
2006-11-23 |
Fey Georg H |
Bispecific antibody devoid of Fc region and method of treatment using same
|
JP4557003B2
(ja)
|
2005-07-01 |
2010-10-06 |
株式会社村田製作所 |
多層セラミック基板およびその製造方法ならびに多層セラミック基板作製用複合グリーンシート
|
EP1907424B1
(en)
|
2005-07-01 |
2015-07-29 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
DE602005018477D1
(de)
|
2005-08-26 |
2010-02-04 |
Pls Design Gmbh |
Bivalente IgY Antikörperkonstrukte für diagnostische und therapeutische Anwendungen
|
PE20070427A1
(es)
|
2005-08-30 |
2007-04-21 |
Novartis Ag |
Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
|
WO2007044887A2
(en)
|
2005-10-11 |
2007-04-19 |
Transtarget, Inc. |
Method for producing a population of homogenous tetravalent bispecific antibodies
|
EP1777294A1
(en)
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
|
EP1962961B1
(en)
|
2005-11-29 |
2013-01-09 |
The University Of Sydney |
Demibodies: dimerisation-activated therapeutic agents
|
CA2631812C
(en)
|
2005-12-02 |
2023-08-29 |
Peter Palese |
Chimeric viruses presenting non-native surface proteins and uses thereof
|
DK2343299T3
(en)
|
2005-12-13 |
2016-01-18 |
Incyte Holdings Corp |
Heteroberl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors
|
LT2481753T
(lt)
|
2005-12-13 |
2018-05-25 |
Eli Lilly And Company |
Anti-il-17 antikūnai
|
EP2347775B1
(en)
|
2005-12-13 |
2020-04-15 |
President and Fellows of Harvard College |
Scaffolds for cell transplantation
|
WO2007133822A1
(en)
|
2006-01-19 |
2007-11-22 |
Genzyme Corporation |
Gitr antibodies for the treatment of cancer
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
CA2638794A1
(en)
|
2006-02-15 |
2007-08-23 |
Imclone Systems Incorporated |
Functional antibodies
|
NZ591252A
(en)
|
2006-03-17 |
2012-06-29 |
Biogen Idec Inc |
Methods of designing antibody or antigen binding fragments thereof with substituted non-covarying amino acids
|
CA2646965C
(en)
|
2006-03-24 |
2016-06-21 |
Jonathan H. Davis |
Engineered heterodimeric protein domains
|
WO2007112362A2
(en)
|
2006-03-24 |
2007-10-04 |
The Regents Of The University Of California |
Construction of a multivalent scfv through alkyne-azide 1,3-dipolar cycloaddition
|
WO2007114325A1
(ja)
|
2006-03-31 |
2007-10-11 |
Chugai Seiyaku Kabushiki Kaisha |
二重特異性抗体を精製するための抗体改変方法
|
LT2010528T
(lt)
|
2006-04-19 |
2017-12-27 |
Novartis Ag |
6-o-pakeistieji benzoksazolo junginiai bei csf-1r signalo perdavimo slopinimo būdai
|
UA93548C2
(uk)
|
2006-05-05 |
2011-02-25 |
Айерем Елелсі |
Сполуки та композиції як модулятори хеджхогівського сигнального шляху
|
US8501185B2
(en)
|
2006-05-25 |
2013-08-06 |
Bayer Healthcare Llc |
Dimeric molecular complexes
|
US20070274985A1
(en)
|
2006-05-26 |
2007-11-29 |
Stefan Dubel |
Antibody
|
NZ612319A
(en)
|
2006-06-12 |
2015-04-24 |
Emergent Product Dev Seattle |
Single-chain multivalent binding proteins with effector function
|
PE20080951A1
(es)
|
2006-08-02 |
2008-09-11 |
Novartis Ag |
DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
|
PE20081214A1
(es)
|
2006-08-18 |
2008-09-24 |
Novartis Ag |
Anticuerpo especifico prlr y sus usos
|
CA2661042C
(en)
|
2006-08-18 |
2012-12-11 |
Armagen Technologies, Inc. |
Agents for blood-brain barrier delivery
|
BRPI0714635A2
(pt)
|
2006-08-21 |
2013-06-18 |
Genentech Inc |
compostos, composiÇço farmacÊutica, mÉtodo para inibir, o crescimento celular anormal ou tratar uma disfunÇço hiperproliferativa, mÉtodo para tratar uma doenÇa inflamatària e mÉtodo para tratar uma doenÇa autoimune
|
PL2059533T3
(pl)
|
2006-08-30 |
2013-04-30 |
Genentech Inc |
Przeciwciała wieloswoiste
|
US7767206B2
(en)
|
2006-10-02 |
2010-08-03 |
Amgen Inc. |
Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
|
GB0620894D0
(en)
|
2006-10-20 |
2006-11-29 |
Univ Southampton |
Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
|
EP3284825B1
(en)
|
2006-11-02 |
2021-04-07 |
Biomolecular Holdings LLC |
Methods of producing hybrid polypeptides with moving parts
|
CN103288833B
(zh)
|
2006-11-22 |
2018-01-12 |
因塞特控股公司 |
作为激酶抑制剂的咪唑并三嗪和咪唑并嘧啶
|
EP2114432B1
(en)
|
2006-12-05 |
2014-07-30 |
Memgen LLC |
Methods of increasing cancer sensitivity to chemotherapeutic agents using chimeric isf35
|
DK2091918T3
(en)
|
2006-12-08 |
2014-12-01 |
Irm Llc |
Compounds and Compositions as Protein Kinase Inhibitors
|
US20100178684A1
(en)
|
2006-12-21 |
2010-07-15 |
Woo Savio L C |
Transgenic oncolytic viruses and uses thereof
|
ES2667863T3
(es)
|
2007-03-29 |
2018-05-14 |
Genmab A/S |
Anticuerpos biespecíficos y métodos de producción de los mismos
|
CA2682605A1
(en)
|
2007-04-18 |
2008-10-30 |
Zymogenetics, Inc. |
Single chain fc, methods of making and methods of treatment
|
PL2170959T3
(pl)
|
2007-06-18 |
2014-03-31 |
Merck Sharp & Dohme |
Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1
|
WO2009002401A2
(en)
|
2007-06-21 |
2008-12-31 |
President And Fellows Of Harvard College |
Scaffolds for cell collection or elimination
|
CA2691785C
(en)
|
2007-06-27 |
2017-01-10 |
Marine Polymer Technologies Inc. |
Complexes of il-15 and il-15ralpha and uses thereof
|
PT2175884T
(pt)
|
2007-07-12 |
2016-09-21 |
Gitr Inc |
Terapias de combinação empregando moléculas de ligação a gitr
|
CN101952312A
(zh)
|
2007-07-31 |
2011-01-19 |
米迪缪尼有限公司 |
多特异性表位结合蛋白及其应用
|
ES2628395T3
(es)
|
2007-08-15 |
2017-08-02 |
Bayer Pharma Aktiengesellschaft |
Anticuerpo regulado por proteasa
|
AU2008328779B2
(en)
|
2007-11-27 |
2014-06-05 |
Ablynx N.V. |
Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
|
CN101932608A
(zh)
|
2007-11-30 |
2010-12-29 |
葛兰素集团有限公司 |
抗原结合构建体
|
MX2010006800A
(es)
|
2007-12-19 |
2010-10-05 |
Genentech Inc |
5-anilinoimidazopiridinas y metodos de uso de las mismas.
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
US8592562B2
(en)
|
2008-01-07 |
2013-11-26 |
Amgen Inc. |
Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
|
RU2531758C2
(ru)
|
2008-02-11 |
2014-10-27 |
Куретек Лтд. |
Моноклональные антитела для лечения опухолей
|
CN102006891B
(zh)
|
2008-02-13 |
2017-04-26 |
哈佛学院董事会 |
连续的细胞程序化装置
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
EP2252293B1
(en)
|
2008-03-14 |
2018-06-27 |
Intellikine, LLC |
Kinase inhibitors and methods of use
|
AR070924A1
(es)
|
2008-03-19 |
2010-05-12 |
Novartis Ag |
Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
|
MY187131A
(en)
|
2008-05-21 |
2021-09-02 |
Incyte Corp |
Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
|
UA103478C2
(ru)
|
2008-05-23 |
2013-10-25 |
Новартіс Аг |
Производные хинолинов и хиноксалинов как ингибиторы протеинтирозинкиназы
|
PE20100087A1
(es)
|
2008-06-25 |
2010-02-08 |
Irm Llc |
Compuestos y composiciones como inhibidores de cinasa
|
WO2010003118A1
(en)
|
2008-07-02 |
2010-01-07 |
Trubion Pharmaceuticals, Inc. |
Tgf-b antagonist multi-target binding proteins
|
CA2730106A1
(en)
|
2008-07-08 |
2010-01-14 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
BRPI0915928B8
(pt)
|
2008-07-17 |
2021-05-25 |
Novartis Ag |
anticorpo isolado ou proteína funcional e composição farmacêutica compreendendo os mesmos
|
US20100041663A1
(en)
|
2008-07-18 |
2010-02-18 |
Novartis Ag |
Organic Compounds as Smo Inhibitors
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
CA2734802C
(en)
|
2008-08-22 |
2016-05-31 |
Novartis Ag |
Pyrrolopyrimidine compounds as cdk inhibitors
|
AU2009288730B2
(en)
|
2008-08-25 |
2013-06-20 |
Amplimmune, Inc. |
Compositions of PD-1 antagonists and methods of use
|
US20110223188A1
(en)
|
2008-08-25 |
2011-09-15 |
Solomon Langermann |
Targeted costimulatory polypeptides and methods of use to treat cancer
|
EA020136B1
(ru)
|
2008-09-02 |
2014-08-29 |
Новартис Аг |
Производные пиколинамида в качестве ингибиторов киназы
|
UA104147C2
(uk)
|
2008-09-10 |
2014-01-10 |
Новартис Аг |
Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
|
CN102149820B
(zh)
|
2008-09-12 |
2014-07-23 |
国立大学法人三重大学 |
能够表达外源gitr配体的细胞
|
CA2738429C
(en)
|
2008-09-26 |
2016-10-25 |
Intellikine, Inc. |
Heterocyclic kinase inhibitors
|
ES2621141T3
(es)
|
2008-11-28 |
2017-07-03 |
Novartis Ag |
Combinación farmacéutica que comprende un inhibidor de Hsp 90 y un inhibidor de mTOR
|
PL2376535T3
(pl)
|
2008-12-09 |
2017-09-29 |
F.Hoffmann-La Roche Ag |
Przeciwciała ANTY-PD-L1 i ich zastosowanie do nasilania działania limfocytów T
|
US8591881B2
(en)
|
2009-02-05 |
2013-11-26 |
Mount Sinai School Of Medicine |
Chimeric Newcastle disease viruses and uses thereof
|
ES2629337T3
(es)
|
2009-02-09 |
2017-08-08 |
Inserm - Institut National De La Santé Et De La Recherche Médicale |
Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
|
UA103918C2
(en)
|
2009-03-02 |
2013-12-10 |
Айерем Элелси |
N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
|
EP2424567B1
(en)
|
2009-04-27 |
2018-11-21 |
OncoMed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
CA2760385C
(en)
|
2009-04-30 |
2021-04-20 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Anti ceacam1 antibodies and methods of using same
|
EP2445903B1
(en)
|
2009-06-26 |
2014-03-26 |
Novartis AG |
1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
|
JO3002B1
(ar)
|
2009-08-28 |
2016-09-05 |
Irm Llc |
مركبات و تركيبات كمثبطات كيناز بروتين
|
KR101790802B1
(ko)
|
2009-09-03 |
2017-10-27 |
머크 샤프 앤드 돔 코포레이션 |
항-gitr 항체
|
IT1395574B1
(it)
|
2009-09-14 |
2012-10-16 |
Guala Dispensing Spa |
Dispositivo di erogazione
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
SI3279215T1
(sl)
|
2009-11-24 |
2020-07-31 |
Medimmune Limited |
Usmerjena vezavna sredstva proti B7-H1
|
JP2013512251A
(ja)
|
2009-11-24 |
2013-04-11 |
アンプリミューン、インコーポレーテッド |
Pd−l1/pd−l2の同時阻害
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
EP2519544A1
(en)
|
2009-12-29 |
2012-11-07 |
Emergent Product Development Seattle, LLC |
Polypeptide heterodimers and uses thereof
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
AU2011244282A1
(en)
|
2010-04-20 |
2012-11-15 |
Genmab A/S |
Heterodimeric antibody Fc-containing proteins and methods for production thereof
|
KR101846590B1
(ko)
|
2010-06-11 |
2018-04-09 |
교와 핫꼬 기린 가부시키가이샤 |
항 tim-3 항체
|
WO2012004367A1
(en)
|
2010-07-09 |
2012-01-12 |
N.V. Organon |
Agonistic antibody to cd27
|
UA114883C2
(uk)
|
2010-08-20 |
2017-08-28 |
Новартіс Аг |
Антитіло до рецептора епідермального фактора росту-3 (her3)
|
EA029793B1
(ru)
|
2010-08-23 |
2018-05-31 |
Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем |
Антитела к ох40 и способы их применения
|
AU2011305476B2
(en)
|
2010-09-21 |
2016-12-01 |
Altor Bioscience Corporation |
Multimeric IL-15 soluble fusion molecules and methods of making and using same
|
KR102157971B1
(ko)
|
2010-10-06 |
2020-09-18 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
재료에 기초한 세포 치료를 위한 주사 가능한 기공 형성 하이드로겔
|
WO2012149358A1
(en)
|
2011-04-28 |
2012-11-01 |
President And Fellows Of Harvard College |
Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
|
CN103732623B
(zh)
|
2011-06-03 |
2017-09-29 |
佐马技术有限公司 |
对TGF‑β具有特异性的抗体
|
EP2714073B1
(en)
|
2011-06-03 |
2021-03-10 |
President and Fellows of Harvard College |
In situ antigen-generating cancer vaccine
|
WO2012177624A2
(en)
|
2011-06-21 |
2012-12-27 |
The Johns Hopkins University |
Focused radiation for augmenting immune-based therapies against neoplasms
|
BR112014002353B1
(pt)
|
2011-08-01 |
2022-09-27 |
Genentech, Inc |
Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
CN110964115B
(zh)
|
2011-10-27 |
2024-03-12 |
健玛保 |
异二聚体蛋白的生成
|
DK2785375T3
(da)
|
2011-11-28 |
2020-10-12 |
Merck Patent Gmbh |
Anti-pd-l1-antistoffer og anvendelser deraf
|
WO2013082366A1
(en)
|
2011-12-01 |
2013-06-06 |
The Brigham And Women's Hospital, Inc. |
Anti-ceacam1 recombinant antibodies for cancer therapy
|
CN109125718A
(zh)
|
2012-01-13 |
2019-01-04 |
哈佛学院董事会 |
在结构聚合装置中tlr激动剂的控制传递
|
US8815926B2
(en)
|
2012-01-26 |
2014-08-26 |
Novartis Ag |
Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
EP2831047B1
(en)
|
2012-03-29 |
2017-05-03 |
Advanced Cancer Therapeutics, LLC |
Pfkfb3 inhibitor and methods of use as an anti-cancer therapeutic
|
AU2013249366B2
(en)
|
2012-04-16 |
2018-02-01 |
President And Fellows Of Harvard College |
Mesoporous silica compositions for modulating immune responses
|
EP2838548B1
(en)
|
2012-04-17 |
2023-07-19 |
University of Washington through its Center for Commercialization |
Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof
|
AU2013261130A1
(en)
|
2012-05-15 |
2014-10-23 |
Novartis Ag |
Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
|
CN104334529B
(zh)
|
2012-05-15 |
2017-03-15 |
诺华股份有限公司 |
用于抑制abl1、abl2和bcr‑abl1的活性的化合物和组合物
|
JP6078640B2
(ja)
|
2012-05-15 |
2017-02-08 |
ノバルティス アーゲー |
Abl1、abl2およびbcr−abl1の活性を阻害するためのベンズアミド誘導体
|
AU2013261127B2
(en)
|
2012-05-15 |
2015-03-12 |
Novartis Ag |
Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
|
JO3300B1
(ar)
|
2012-06-06 |
2018-09-16 |
Novartis Ag |
مركبات وتركيبات لتعديل نشاط egfr
|
KR101566539B1
(ko)
|
2012-06-08 |
2015-11-05 |
국립암센터 |
신규한 Th2 세포 전환용 에피토프 및 이의 용도
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
CN112587658A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
CA2916638C
(en)
|
2012-07-31 |
2021-01-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of the immune response
|
CA2888896A1
(en)
|
2012-10-24 |
2014-05-01 |
Admune Therapeutics Llc |
Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
|
WO2014072493A1
(en)
|
2012-11-08 |
2014-05-15 |
Novartis Ag |
Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
|
US9408847B2
(en)
|
2012-11-28 |
2016-08-09 |
Novartis Ag |
Combination therapy
|
PT2953969T
(pt)
|
2013-02-08 |
2019-12-03 |
Novartis Ag |
Anticorpos anti-il-17a e utilização dos mesmos no tratamento de distúrbios autoimunes e inflamatórios
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
US9242969B2
(en)
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
MX355945B
(es)
|
2013-03-14 |
2018-05-07 |
Novartis Ag |
3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
|
MY180687A
(en)
|
2013-03-14 |
2020-12-07 |
Icahn School Med Mount Sinai |
Newcastle disease viruses and uses thereof
|
AP2015008700A0
(en)
|
2013-05-18 |
2015-08-31 |
Univ California |
Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
|
CN105188373B
(zh)
|
2013-05-18 |
2017-09-22 |
艾杜罗生物科技公司 |
抑制“干扰素基因刺激蛋白”依赖性信号传导的组合物和方法
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
NZ757060A
(en)
|
2013-09-11 |
2022-07-01 |
Medimmune Ltd |
Anti-b7-h1 antibodies for treating tumors
|
EA032754B1
(ru)
|
2013-11-01 |
2019-07-31 |
Новартис Аг |
Аминогетероарил бензамиды в качестве ингибиторов киназы
|
US9512084B2
(en)
|
2013-11-29 |
2016-12-06 |
Novartis Ag |
Amino pyrimidine derivatives
|
GB201322583D0
(en)
|
2013-12-19 |
2014-02-05 |
Alligator Bioscience Ab |
Antibodies
|
JOP20200094A1
(ar)
*
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
CN113583129A
(zh)
*
|
2014-03-14 |
2021-11-02 |
诺华股份有限公司 |
针对lag-3的抗体分子及其用途
|
CN107001478B
(zh)
|
2014-10-14 |
2022-01-11 |
诺华股份有限公司 |
针对pd-l1的抗体分子及其用途
|